Clinicians can predict which patients with ocular hypertension are most likely to develop primary open-angle glaucoma (POAG) using short-wave automated perimetry, scanning laser polimetry, and confocal laser ophthalmoscopy, as well as the patient’s age, researchers said.
Clinicians will soon have another treatment option for their patients with non-severe primary open-angle glaucoma (POAG). A micro invasive glaucoma surgical (MIGS) device (CyPass Micro-Stent, Alcon) has been approved by the FDA for use in patients with mild-moderate PAOG in conjunction with cataract surgery.
The combination of MICS and MIGS can offer an effective surgical treatment for POAG when the reduction of IOP following cataract surgery alone is not sufficient to reduce a patient’s need for glaucoma therapies.
An investigational glaucoma device that shunts aqueous from the anterior chamber to a sub-conjunctival/sub-Tenon’s pouch is being evaluated in a prospective study of 35 eyes operated on at two centers.